Agilent Buying Cancer Diagnostics Company Dako for $2.2B | GenomeWeb

The story has been updated to include comments from a conference call.

NEW YORK (GenomeWeb News) – Agilent Technologies and Swedish private equity firm EQT today announced that Agilent will acquire cancer diagnostics firm Dako from EQT for $2.2 billion.

The deal, the largest in Agilent's history, is expected to close within the next 60 days and moves Agilent deeper into the diagnostics space.

Agilent is funding the deal entirely with its off-shore cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.